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Abstract
Background: Cardiovascular diseases (CVDs) are one of the global leading causes of concern due to the rising
prevalence and consequence of mortality and disability with a heavy economic burden. The objective of the
current study was to analyze the trend in CVD incidence, mortality, and mortality-to-incidence ratio (MIR) across the
world over 28 years.
Methods: The age-standardized CVD mortality and incidence rates were retrieved from the Global Burden of
Disease (GBD) Study 2017 for both genders and different world super regions with available data every year during
the period 1990–2017. Additionally, the Human Development Index was sourced from the United Nations
Development Programme (UNDP) database for all countries at the same time interval. The marginal modeling
approach was implemented to evaluate the mean trend of CVD incidence, mortality, and MIR for 195 countries and
separately for developing and developed countries and also clarify the relationship between the indices and
Human Development Index (HDI) from 1990 to 2017.
Results: The obtained estimates identified that the global mean trend of CVD incidence had an ascending trend
until 1996 followed by a descending trend after this year. Nearly all of the countries experienced a significant
declining mortality trend from 1990 to 2017. Likewise, the global mean MIR rate had a significant trivial decrement
trend with a gentle slope of 0.004 over the time interval. As such, the reduction in incidence and mortality rates for
developed countries was significantly faster than developing counterparts in the period 1990–2017 (p < 0.05).
Nevertheless, the developing nations had a more rather shallow decrease in MIR compared to developed ones.
(Continued on next page)
© The Author(s). 2021 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License,
which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if
changes were made. The images or other third party material in this article are included in the article's Creative Commons
licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons
licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain
permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the
data made available in this article, unless otherwise stated in a credit line to the data.
* Correspondence: fzayeri@gmail.com
2Proteomics Research Center and Department of Biostatistics, School of
Allied Medical Sciences, Shahid Beheshti University of Medical Sciences,
Tehran, Iran
Full list of author information is available at the end of the article
Amini et al. BMC Public Health          (2021) 21:401 
https://doi.org/10.1186/s12889-021-10429-0
(Continued from previous page)
Conclusions: Generally, the findings of this study revealed that there was an overall downward trend in CVD
incidence and mortality rates, while the survival rate of CVD patients was rather stable. These results send a
satisfactory message that global effort for controlling the CVD burden was quite successful. Nonetheless, there is an
urgent need for more efforts to improve the survival rate of patients and lower the burden of this disease in some
areas with an increasing trend of either incidence or mortality.
Keywords: Cardiovascular disease, Mortality, Incidence, Mortality-to-incidence ratio, Generalized estimating equation
methodology, Marginal model, Human development index, Trend,
Background
Cardiovascular disease (CVD) is known as the leading
cause of global death and one of the most serious health
problems throughout the world. Commonly, CVD can
refer to a class of diseases that involves the heart or
blood vessels. This disease consists of stroke, heart fail-
ure, hypertensive heart disease, rheumatic heart disease,
peripheral arterial disease, and a number of other vascu-
lar, and cardiac problems. However, CVD which has
been recognized as the leading cause of morbidity and
mortality, is an important contributor to the cost of
medical care [1]. In 2016, CVD was responsible for
nearly one-third of all deaths across the globe [2]. Over
the last decades, although the age-standardized mortality
rates of CVD declined by 27.3%, the number of deaths
increased by 42.4% from 1990 to 2015 [3]. On the other
hand, CVD led to over 17 million deaths, 330 million
years of life lost and 35.6 million years lived with disabil-
ity in 2017 worldwide [4, 5]. Meanwhile, it was projected
that CVD would be the cause of more than 23 million
deaths in 2030 around the world [6]. In the past decades,
although developing countries have experienced higher
rates of death from CVD, this disease was more incident
in developed countries [7]. According to the World
Health Organization (WHO), over three-quarters of
CVD deaths have occurred in low- and middle-income
countries which is a growing epidemic problem in recent
years [8]. The high burden of CVD can be attributed to
other related factors such as diabetes, obesity, lack of
physical activity, hypertension, unhealthy diet, and
excessive alcohol consumption [9]. Today, CVD is re-
sponsible for a remarkable reduction in quality of life
and life expectancy and also imposes huge costs on
health systems in different countries.
Accurate estimation of disease burden plays a key role
in establishing convenient public health policies. To
measure the burden of CVD, different outcome parame-
ters can be used. There are some indices such as preva-
lence, incidence, mortality, and survival which can
provide valuable information about the current situation
and help the policy makers to organize the available
resources. In general, the incidence and mortality rates
of CVD vary from region to region because of several
factors like lifestyle, dietary habits, appropriate health
care accessibility, and so on. For example, people with a
lower level of education in low-income and middle-
income countries have a higher incidence of mortality
from CVD [10]. Notably, assessing the patterns of differ-
ences in disease incidence and mortality rates is of inter-
national interest owing to highlighting the trends and
regional differences which help to figure out the etiology
of CVD. In this context, the Mortality-to-Incidence
Ratio (MIR) is an alternative index that has been com-
monly used to evaluate the burden of disease by present-
ing mortality after accounting for incidence. Clearly, this
ratio determines whether a country or a region has a
higher or lower mortality for a specific condition,
normalized to its incidence. Additionally, it is a simple
and common proxy for the 5-year relative survival of the
patients [11, 12]. More specifically, the MIR could be
used as a helpful indicator for screening and treating
some diseases.
During recent years, various studies have indicated
that the incidence and mortality can be affected by eco-
nomic and social disparities which reflect the regional
disparities in human development. Human development
index (HDI) is one of the important approved indicators
for determining the progress, living conditions, and hu-
man development of different countries. This index,
which is specified by the World Bank, combines a coun-
try’s per-capita gross national income (GNI) [13]. The
HDI comprises socio-economic variables that affect
health and national development factors of people such
as political rights, mortality rate, and education. HDI is
calculated as a simple arithmetic mean of three indexes
reflecting longevity, knowledge, and standard of living.
Longevity is measured by life expectancy at birth, know-
ledge is quantified by potential years of education, and
standard of living is represented by income or gross na-
tional product (GDP) per capita [14].
Over the previous decades, several epidemiological
studies have examined the incidence and mortality
trends of CVD in different parts of the world. In a
study conducted by Smolina et al., it was reported
that a 50% decline in age standardized mortality
occurred in England between 2002 and 2010 [15]. In
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another study, Sidney et al. showed that the CVD
mortality rate decreased since 2011 in United States
which might be due to remarkable improvement in
population-level CVD prevention [16]. It was also
revealed that the trend of age standardized CVD mor-
tality rates in high-income regions has dramatically
reduced during the last 30 years whereas this trend
has slightly declined or even increased in most low
and middle income countries [17] .
Up to now, there are no published studies about asses-
sing the time trend patterns of CVD incidence and mor-
tality rates in various parts of the world via more
advanced statistical techniques. Besides, no published
research is available about evaluating the temporal trend
of CVD MIR globally to date. Also, No evidence based
document is currently available about the association be-
tween the trend of CVD incidence, mortality, and MIR
and HDI using more complex statistical modeling ap-
proaches. However, examining time trends of CVD indi-
ces across the world, as well as investigating the effect of
development factor on the indices trends can be import-
ant to look into avenues for further improvement. Thus,
the novelty of the present study lies in achieving the fol-
lowing specific objectives: a) to assess the mean trends
in age-standardized CVD incidence, mortality, and MIR
rates for the total world and different super regions of
the Institute for Health Metrics and Evaluation (IHME)
in the period 1990–2017 and b) to determine the longi-
tudinal relationship between age-standardized CVD inci-
dence, mortality, and MIR rates and HDI during the
specified time interval using the marginal modeling
approach which has a three-part specification in terms
of a regression model for the mean response. To achieve
these goals, the age-standardized CVD incidence and
mortality rates data was extracted from the Global
Burden of Disease (GBD) Study 2017.
Methods
Data sources
In this study, the information from the GBD free online
database (GBD study 2017) on age-standardized CVD
mortality and incidence rates per 100,000 persons was
extracted from 1990 to 2017 for both genders. GBD is
an international cooperative project that globally, region-
ally, and nationally estimates the disease burden for total
countries and is managed by the IHME which provides
the world’s most important health measurements. The
GBD data sets are gathered and analyzed by a consor-
tium of more than 1800 researchers in more than 100
countries. GBD is the most comprehensive worldwide
epidemiological study which contains burden of disease
indices such as incidence, mortality, prevalence, years of
life lost (YLL), years lived with disability (YLD), and dis-
ability adjusted life years (DALY) for different diseases
and injuries. Furthermore, the GBD data is provided by
different organizations like WHO Global Health Obser-
vatory, World Bank Open Data, and the Inter-university
Consortium for Political and Social Research [4, 5]. The
IHME has classified all countries into seven distinct
parts referred to super region according to geographical
and economic criteria: Central Europe, Eastern Europe,
and Central Asia (CEEECA) including 29 countries,
High Income (HI) including 35 countries, Latin America
and Caribbean (LAC) including 31 countries, North
Africa and Middle East (NAME) including 21 countries,
South Asia (SA) including 5 countries, Southeast Asia,
East Asia, and Oceania (SAEAO) including 28 countries,
and Sub-Saharan Africa (SSA) including 46 countries.
Human Development Index, introduced by the United
Nations Development Programme (UNDP) in 1990, is
defined as the average achievement of three dimensions
including life expectancy at birth as the health indicator,
gross national income per capita as the economic indica-
tor, and mean and expected years of schooling for
school-age children and average years of schooling in
the adult population as the educational indicator. The
geometric mean of the three indicators provides the ag-
gregate value of HDI for a given country in a year [18].
The numerical value of the HDI is ranged from zero
(worst) to one (best). This socio-economic index suggests
the most up-to-date information on global development
and contains national, regional, and global estimates. In
this study, countries with HDI values of less than 0.788
were considered as developing and those with HDI values
of 0.788 or higher as developed [14]. The HDI data for
each country in the period of 1990–2017 was obtained
from updates of the UNDP database [19].
Variables under study
In the present research, the considered outcomes under
study were the CVD incidence, mortality, and mortality-
to-incidence ratio for each of the countries in the years
1990 to 2017. Calculation of the MIR provides an alter-
native means that could expand the interpretation and
understanding of the relationship between the burden of
disease by presenting mortality and incidence. This
measurement can help us to determine the demo-
graphic, environmental, and social factors which might
lead to changes in mortality rates according to incidence
rates. Notably, the MIR can explore and address the hid-
den differences in disease incidence [20]. Further, using
this index, one can forecast burdens, trends, and retro-
spectively evaluate populations with shorter or longer
five-year survival. This information can be useful for
disease prevention, diagnosis proficiency, treatment
effectiveness, and making decisions to gain better sur-
vival [21, 22]. A retrospective study found that there is a
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positive correlation between the MIR values and health-
care system ranking for different countries [20].
In the current study, the MIR value for each country
was calculated as the publicly available data of age-
standardized mortality rate divided by age-standardized
incidence rate of CVD in both genders from the GBD
study 2017, separately in each year of the study. As men-
tioned, this index was used as a valid proxy for 5-year
relative survival of CVD patients. In addition, for each
country the development factor as a binary variable (0 =
Developing, 1 = Developed) was considered as the inde-
pendent predictor of incidence, mortality, and MIR in
the statistical analysis process.
Statistical analysis
Firstly, summary statistics related to CVD incidence,
mortality, and MIR were provided for each IHME super
region from 1990 to 2017. Likewise, the average annual
trends of the CVD incidence, mortality, and MIR indices
were exhibited graphically by super region and develop-
ment factor over the study period.
In the next step, the marginal modeling approach and
Generalized Estimating Equations (GEE) methodology
utilized to assess the longitudinal effect of development
factor on incidence, mortality, and MIR indices. The
GEE is a population-level approach which enables us to
obtain the population-averaged estimates of the model
parameters [23]. To investigate the time trend of CVD
burden indices, the following marginal model was fitted,
separately for developed and developing countries:
μij ¼ β0 þ β1 timeij ð1Þ
where μij represents the mean incidence, mortality, or
MIR for the ith country (i = 1,2, …,195) in the jth year of
the study (j = 0,1, …,27). Here, β0 indicates the mean
starting value of the index (intercept) and β1 is the
model slope which shows the mean annual change in
these indices. The time covariate shows the study time
point (time = 0, 1, …,27 as a proxy for year = 1990, 1991,
…, 2017). Notably, in some areas, the mean trend of the
outcome under study might have a non-linear form. To
capture the non-linear nature of these trends, the follow-
ing spline model could be utilized as:
μij ¼ β0 þ β1 timeij þ β2 timeij − t
 
þ ð2Þ
where t∗ indicates the turning point in the mean trend
plot and the covariate (timeij − t
∗)+ = 0 if time ≤ t
* and
(timeij − t
∗)+ = timeij − t
∗ if timeij > t
∗. It should be noted
that the interpretation of the estimates in marginal
models is rather analogous to the common simple linear
regression models. All analyses were conducted using
the STATA 14.0 (https://www.stata.com) and SPSS 22.0
(SPSS Inc., Chicago, IL, USA) softwares. P-values less
than 0.05 were regarded statistically significant.
Results
A total of 195 countries were included in the current
study to assess the trend of CVD incidence, mortality,
and MIR in the period 1990–2017. Figure 1 represents
these trends in different IHME super regions. As can be
seen in Fig. 1, the incidence rates were rather steady for
HI, LAC, NAME, SSA, and SAEAO over the 28-year
study period. Also, the countries in CEEECA had a mod-
erate rise in CVD incidence over time until 2010, but
then they had reached a steep decrementing trend dur-
ing 2010–2017. Likewise, SA experienced a marked in-
creasing trend of CVD incidence between 1990 and
2006, but it had a stable trend from 2006 to 2017. On
the other hand, with the exception of SA region which
had an increasing trend between 2006 and 2010, HI,
LAC, NAME, SAEAO, and SSA regions experienced a
downward trend in mortality rates. Additionally, the
CEEECA countries had an upward trend in their CVD
death between 1990 and 1995 and a declining pattern
during the years 1995–2017. Accordingly, trends in age-
standardized MIR from CVD among SSA, SAEAO,
NAME, LAC, and HI countries declined sharply
throughout the period. In CEEECA, the pattern of MIR
was incremental in 1990–1994 with a peak in 1994 and
a subsequent reduction from 1994 to 2017. Furthermore,
the trend of MIR from CVD between 2004 and 2010
was, in fact, increasing and started to decrease consist-
ently after these years in SA.
Table 1 shows the descriptive statistics for CVD inci-
dence, mortality, and MIR in each IHME super region
and total countries in 5-year intervals (and year 2017).
Based on the Table, one can observe that countries in
the HI region have experienced the highest incidence
rates and the lowest mortality rates and MIRs in the
period 1990–2017. In this time interval, SA countries
had the lowest incidence rate at the starting point of the
study and after the year 1995, the lowest incidence rate
was related to LAC. From the mortality rate point of
view, the CEEECA super region had the highest values
in the study period. In addition, the maximum MIR
value belonged to the SAEAO super region in the year
1990, while the highest ratio was related to SA in the
ending year of the study. Besides, at the beginning and
ending of the study, the minimum MIR value of CVD
was observed among HI countries. Moreover, last row of
Table 1 displays that all countries had a relatively rapid
increment in mean IR until 1997 and then continued
with a sharp reduction until the ending year of the
study.
The trends of incidence rate (IR), mortality rate (MR),
and MIR, separately for developing and developed
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countries are depicted in Fig. 2. As seen, it seems that
CVD IR and MR fell substantially and MIR slightly
decreased in both developed and developing countries
over the follow-up time. The descriptive statistics for
CVD IR, MR, and MIR values, separately for the
developing and developed countries in selected years are
summarized in Table 2. With respect to Table 2, one
can observe that developing countries had lower CVD
IR and higher MR and MIR values compared to devel-
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Fig. 1 Mean trends of CVD (a) incidence, (b) mortality, and (c) MIR rates per 100,000 individuals by IHME super regions in the period 1990–2017




1990 1995 2000 2005 2010 2015 2017
CEEECA Incidence 1191.2 (198.1)b 1202.4 (182.7) 1205.6 (171.4) 1206 (175.3) 1202.1 (181.5) 1162.9 (187.6) 1137.5 (191.8)
Mortality 492.2 (66.9) 540.3 (107.9) 499.9 (115.1) 495.5 (144.2) 438.6 (129.2) 398.8 (123.5) 387.1 (120.8)
MIR 0.42 (0.09) 0.46 (0.12) 0.42 (0.12) 0.42 (0.14) 0.37 (0.13) 0.35 (0.13) 0.35 (0.14)
HI Incidence 1217.3 (168.5) 1221.1 (179.9) 1213.6 (198.4) 1206.8 (208.7) 1200.4 (209.3) 1189.5 (203.6) 1183.7 (199.6)
Mortality 283.7 (52.4) 246.8 (44.8) 210.5 (42.2) 175.1 (37.9) 145.8 (33.5) 130.2 (31.8) 128.9 (32.3)
MIR 0.23 (0.05) 0.20 (0.04) 0.17 (0.04) 0.14 (0.03) 0.12 (0.03) 0.11 (0.03) 0.11 (0.03)
LAC Incidence 715.8 (57.8) 720.03 (57.7) 712.3 (55.02) 705.2 (54.2) 698.6 (51.2) 693.2 (48.9) 691.2 (48.2)
Mortality 303.3 (94.2) 282.3 (84.1) 241.5 (77.7) 219.8 (73.1) 203.8 (71.5) 200.2 (74.1) 198.7 (71.8)
MIR 0.41 (0.09) 0.38 (0.08) 0.33 (0.08) 0.30 (0.08) 0.28 (0.08) 0.28 (0.09) 0.28 (0.08)
NAME Incidence 1000.3 (110.1) 1011.8 (115.7) 1005.1 (111.3) 989.5 (99.6) 979.1 (86.8) 961.4 (76.1) 952.3 (72.7)
Mortality 464.1 (126.2) 451.9 (136.9) 420.5 (137.1) 378.3 (130.9) 342.8 (127.1) 315.1 (125.7) 308.9 (126.1)
MIR 0.45 (0.08) 0.43 (0.09) 0.41 (0.09) 0.37 (0.09) 0.34 (0.10) 0.32 (0.10) 0.31 (0.11)
SA Incidence 707.8 (71.4) 725.2 (85.4) 735.6 (98.1) 748 (102.1) 745.1 (98.4) 733.1 (87.4) 725.8 (81.2)
Mortality 314 (38.2) 310.3 (70.7) 308.1 (81.4) 311.7 (89.4) 316.9 (85.5) 300.2 (77.3) 296.2 (77.1)
MIR 0.44 (0.02) 0.42 (0.04) 0.41 (0.05) 0.41 (0.06) 0.42 (0.06) 0.40 (0.05) 0.40 (0.05)
SAEAO Incidence 838.1 (78.03) 854.6 (79.1) 854.9 (82.1) 851.9 (87.3) 840.5 (86.1) 828.4 (87.9) 823.2 (90.1)
Mortality 404.7 (118.7) 392.5 (119.9) 378.1 (123.7) 354.1 (127.6) 333.8 (131.5) 319.5 (128.8) 314.8 (126.2)
MIR 0.48 (0.12) 0.45 (0.12) 0.43 (0.12) 0.41 (0.12) 0.39 (0.12) 0.38 (0.13) 0.37 (0.12)
SSA Incidence 740.1 (43.7) 750.5 (45.9) 749.4 (46.1) 745.1 (46.2) 734.1 (43.3) 720.6 (38.2) 714.5 (35.6)
Mortality 351.5 (84.7) 347.4 (81.6) 340.6 (68.1) 320.8 (68.2) 302.1 (69.2) 284.3 (65.4) 276.7 (62.2)
MIR 0.47 (0.09) 0.46 (0.09) 0.45 (0.07) 0.42 (0.07) 0.40 (0.08) 0.39 (0.08) 0.38 (0.08)
Global Incidence 928.7 (239.8) 938.3 (239.2) 935.6 (240.3) 930.5 (241.8) 922.3 (243.1) 906.5 (237.2) 898 (233.2)
Mortality 371.9 (115.7) 365.1 (134.1) 339.1 (133.3) 316.1 (140.9) 288.7 (132.5) 269.8 (125.2) 264.3 (121.8)
MIR 0.41 (0.12) 0.40 (0.13) 0.37 (0.13) 0.35 (0.13) 0.32 (0.13) 0.31 (0.13) 0.30 (0.13)
a CEEECA Central Europe, Eastern Europe, and Central Asia, HI High Income, LAC Latin America and Caribbean, NAME North Africa and Middle East, SA South Asia,
SAEAO Southeast Asia, East Asia, and Oceania, SSA Sub-Saharan Africa. b Mean (Standard deviation)
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that the trends in IR and MR decreased with a relatively
rapid slope in both developed and developing areas.
Nonetheless, the rates of MIR had rather fixed decreased
trends with gentle slopes over and stayed steady till 2017
across the countries. Also, as can be seen, there were
substantial gaps between trends of incidence, mortality,
and MIR. In addition, Fig. 3 demonstrates the age-
standardized IR, MR, and MIR trends for the entire
world from 1990 to 2017. As shown in Fig. 3, the mean
CVD MR and MIR trend declined steeply over the study
interval.
Apparently, as Fig. 2 indicates, since the mean trend of
all the three indices seems to be linear for both the
developed and developing countries, the described
model [1] was applied to estimate the intercept and
slope of the mean trends. Table 3 provides the ob-
tained estimated parameters based on GEE approach.
The estimates for the incidence rates tell us that de-
veloped countries had an intercept of about 378 per
100.000 higher than developing countries. This means
that the mean IR in developed countries was about
378 per 100.000 higher than developing countries in
1990. In addition, the estimated slope for developed
countries was about 1.8 times of the estimate for de-
veloping countries over time. In other words, the
developed countries had steeper IR reduction com-
pared to developing countries. Regarding the esti-
mates for MRs, one can conclude that developed
countries had an intercept of about 105 per 100.000
lower than developing countries. This means that the
mean MR in developed countries was about 105 per
100.000 lower than developing countries in the start-
ing year of the study. The nearly equal estimated
slopes for mean MRs in developed and developing
countries (− 2.87 vs. -2.69) indicate a relatively similar
mean MR reduction for countries in both develop-
ment conditions. Finally, the estimates for the mean
MIRs illustrate that in developed countries, the mean
MIR was about 0.20 lower than developing countries
in 1990. Likewise, the estimated slopes for the mean
MIR in developing countries were two times of the
estimate in developed countries from 1990 to 2017
(− 0.002 vs. -0.001).
Also the mean trends of IR, MR, and MIR was mod-
eled for total countries (Table 3). According to the mean
trends in Fig. 3, since the mean IR trend has a non-
linear shape, the illustrated model [2] in the Methods
section was applied with t∗ = 6 (due to the presence of
the turning point in the year 1996) for this index. In





































































































































































Fig. 2 Mean trends of CVD (a) incidence, (b) mortality, and (c) MIR rates per 100,000 individuals by development factor in the period 1990–2017
Table 2 Mean trend of CVD incidence, mortality, and MIR per 100,000 by development factor over 1990–2017
Countries Index Year
1990 1995 2000 2005 2010 2015 2017
Developing Incidence 901.8 (225.6)a 895.8 (214.8) 880.9 (203.4) 896.4 (210.1) 888.7 (217.8) 878.9 (217.3) 877.1 (230.7)
Mortality 373.9 (116.6) 380.4 (136.3) 362.4 (129.8) 347.4 (137.1) 321.8 (127.3) 309.7 (120.1) 304.4 (117.8)
MIR 0.42 (0.10) 0.42 (0.10) 0.41 (0.10) 0.40 (0.10) 0.38 (0.10) 0.38 (0.10) 0.38 (0.10)
Developed Incidence 1272.1 (185.2) 1246.9 (192.7) 1200.1 (223.1) 1193.7 (219) 1167.6 (236.4) 1100.6 (250.1) 1088.8 (243.9)
Mortality 268.0 (43) 258.7 (76.6) 240.7 (79.8) 219 (91.9) 216.2 (115.6) 204.2 (106.4) 204.1 (107.8)
MIR 0.21 (0.04) 0.21 (0.08) 0.20 (0.08) 0.18 (0.08) 0.19 (0.10) 0.19 (0.10) 0.19 (0.10)
a Mean (Standard deviation)
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MR and MIR, the linear model [1] was utilized to esti-
mate the intercepts and slopes of mean trends for
these two indices. Based on these results, the esti-
mated intercept for CVD incidence rate in all coun-
tries was about 903.19 per 100,000 people in 1990
followed by a positive slope of 4.31 per 100.000 until
the year 1996 and thereafter a slope of 4.31time–5.84
(time–6) from 1996 to 2017. Clearly, the mean CVD
incidence rate has increased annually by 4.31 per
100.000 until 1996 and then has diminished by a fac-
tor of about 1.53 per year of follow-up (4.31–5.84 = −
1.53). Furthermore, the fitted model revealed a statis-
tically significant downward mean mortality rate with
an annual reduction of 3.82 per 100,000 people be-
tween 1990 and 2017 for total countries. Likewise,
the mean MIR has globally decreased with an annual
reduction of 0.004 over the 28-year study period.
Discussion
Cardiovascular diseases as a major concern for global
health, have been the leading cause of global mortal-
ity since 1980. Most epidemiological studies con-
ducted on incidence and mortality rates due to CVD
are descriptive or cross-sectional and identifying the
time trends of CVD incidence along with mortality
are not well documented. Additionally, the effects of
development factor and geographic location on CVD
incidence, mortality, and MIR have not been dis-
cussed and approved in any studies. Therefore, to
characterize and make comparisons this diversity in
distinctive regions with regard to their trends from
1990 to 2017, using proper statistical technique
seems to be necessary with a high degree of accur-












































































Fig. 3 Mean Trends of CVD (a) incidence, (b) mortality, and (c) MIR rates per 100,000 individuals for total world countries in the period 1990–2017
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The results from the GBD 2017 data for CVD inci-
dence indicate that all super regions had a rather steady
decreasing trend during the interval 1990–2017, except
CEEECA and SA super regions which experienced an in-
creasing trend before the year 2010 followed by a down-
ward trend until the ending year of the study. This study
is fairly unique in this field (global trend analysis of
CVD incidence), although a few related studies are avail-
able on the subject of the global incidence trends of
CVD subtypes. For instance, in a study by Khan et al., it
was found that the incidence of age-standardized ische-
mic heart disease has decreased globally in the period
1990–2017. They also stated that this reduction may be
partly due to increasing global awareness about healthy
lifestyle [24]. Based on another study by Avan et al., the
age-standardized incidence rate of stroke has declined
worldwide by 11.3% during the same time interval [25].
Nevertheless, reviewing the available literature on
regional incidence trend of CVD subtypes in different
parts of the world may lead to more controversial re-
sults. For example, Wu et al. demonstrated that the inci-
dence rate of congenital heart disease (CHD) remained
stable from 1990 to 2017 at the global level, whilst a de-
creasing trend was mainly found in Central or South
America and Africa. According to their opinion, the dec-
rement in incidence was largely owing to the rise in the
termination rate following a prenatal diagnosis of CHD
in these regions. By contrast, they reported an increment
in the trend of CHD incidence in countries located in
Western Europe over the last few decades. They con-
cluded that an increase in ventricular septal defect and
atrial septal defect subtypes might be the reason for this
increment in the above mentioned countries [26]. In
addition, as reported by an earlier analysis of GBD data,
the incidence of stroke has declined in most regions par-
ticularly Southern Latin America from 1990 to 2016,
whereas the incidence has increased in East Asia and
Southern Sub-Saharan Africa [27]. In general, educating
people about healthy lifestyle, better global accessibility
to medication for controlling the CVD risk factors and
improvement in CVD prevention strategies might be
considered as the most important reasons for the down-
ward global trend of CVD incidence.
Based on the findings regarding mortality trends, it is
apparent that nearly all countries have experienced a sig-
nificant declining trend over 1990 to 2017 with an an-
nual reduction of 3.82 per 100,000 individuals. This is
particularly prominent in HI countries, with the largest
decrease in CVD mortality. The finding of the descend-
ing trend of CVD mortality is in agreement with some
other reports around the world. For instance, in the
study by Khan et al., it was revealed that the global mor-
tality trend of ischemic heart disease has decreased
slowly but progressively from 1990 to 2017 [24]. In an-
other study, it was shown that the age-standardized
mortality rate of stroke has decreased sharply by 33.4%
over the same time period [25]. However, a study in
Central Asia (which includes low- and middle-income
countries) indicates that the trend of CVD mortality has
increased during the past two decades. The authors con-
cluded that this increment might be the result of insuffi-
cient preventive care, lack of awareness about the
disease signs and symptoms, decreased physical activity,
raised blood pressure, and underutilization of health care
services [28]. Moreover, the results from a study by
Movsisyan et al. suggest that the Central and Eastern
European countries had the highest CVD mortality in
Europe [29]. Overall, advances in treatment, improving
the level of care, and controlling the risk factors of death
in CVD patients (such as smoking, hypertension, and
overweight) are the most important reasons for the
reduction in the mortality rate of this disease [30].
In the current study, the MIR was used as a surrogate
indicator for five-year survival rate of CVD patients.
According to our findings, the overall trend of CVD
MIR has continuously decreased from 0.41 in 1990 to
0.30 in 2017 with a slight slope (mean annual reduction)
of − 0.004. Hopefully, the 26.8% reduction in mean glo-
bal MIR implies that the 5-year survival of CVD patients
had a noticeable rise over this 28-year period. However,
Table 3 Parameter estimates from modeling the mean trend of
CVD incidence, mortality, and MIR by development factor
between 1990 and 2017
HDIa level Index Parameter Estimate SEb P value
Developing Incidence Intercept 904.51 19.50 < 0.001
Time −3.71 0.60 < 0.001
Mortality Intercept 381.14 11.24 < 0.001
Time −2.69 0.41 < 0.001
MIR Intercept 0.42 0.01 < 0.001
Time −0.002 0.0005 < 0.001
Developed Incidence Intercept 1282.77 40.40 < 0.001
Time −6.66 1.44 < 0.001
Mortality Intercept 276.58 10.96 < 0.001
Time −2.87 0.54 < 0.001
MIR Intercept 0.22 0.01 < 0.001
Time −0.001 0.0005 0.009
Total World Incidence Intercept 903.19 16.74 < 0.001
Time 4.31 0.70 < 0.001
(Time-6) −5.84 0.67 < 0.001
Mortality Intercept 370.10 8.35 < 0.001
Time −3.82 0.23 < 0.001
MIR Intercept 0.42 0.009 < 0.001
Time −0.004 0.0003 < 0.001
aHDI Human Development Index. bSE Standard error
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looking at the MIR trend in the IHME super regions
reveals that HI countries had the steepest fall (from 0.23
to 0.11 with more than 50% reduction) during these
years, while countries in SA super region experienced
the lowest reduction (from 0.44 to 0.40 with only 9%
reduction) at the same time interval. It seems the
wealthiest super region has promoted the survival rate of
the patients much more quickly compared to the afore-
mentioned regions. The key reasons for this rise in the
survival rate are probably broader screening programs
and the detection of disease at an earlier stage, promot-
ing knowledge, attitudes, and practices of people around
the world about strategies for preventing cardiovascular
disease, and promoting improved level of care in CVD
patients.
In the present research, the trends of CVD incidence,
mortality, and MIR were compared between developed
and developing countries for the period 1990-2017 via a
marginal model which provides a more accurate evalu-
ation of the longitudinal association between CVD bur-
den and the development status of the region. Our
findings demonstrate that the incidence rate reduction
in developed countries is appreciably faster than that in
developing regions (a slope ratio of 1.8) in the time
period. Likewise, based on the reported descriptive sta-
tistics, CVD incidence in developed countries decreased
by about 14.4% in this 28-year period, while the reduc-
tion in developing countries was only about 2.7% during
the same time period. According to Feigin et al., the
age-standardized incidence of stroke was diminished by
12% in developed countries, whereas it grew by 12% in
developing areas between 1990 and 2010 [31]. The find-
ings from the GBD study 2016 indicate that China and
El Salvador had the highest and lowest age-standardized
incidence of stroke in the period 1990–2016, respectively
[27]. Also, the highest CHD incidence rates were mainly
found in poor African countries such as Somalia and
Burundi, while the lowest rates were mostly observed in
developed countries such as Qatar, Portugal, and France
[26]. A number of studies suggest that there are multiple
factors behind the global reduction in CVD incidence.
These factors could be adopting a healthier lifestyle, pro-
moting the level of knowledge about CVD risk factors
(like obesity, smoking, hypertension, and bad eating
habits), considerable shift in socioeconomic status with in-
creased urbanization and the adoption of western calorie
especially in developing countries [32–34]. Nevertheless,
in several countries, an increasing trend in CVD incidence
has occurred. Namely, the incidence of CVD among South
Korean patients continued to increase during the period
2013–2015 which might be explained by better access to
diagnosis techniques, registration, and reports [35].
In this paper, it was found that both developed and de-
veloping countries experienced a fairly similar declining
trend in CVD mortality from 1990 to 2017. Further-
more, based on descriptive statistics, it was observed that
about 23.8 and 18.5% reduction in mortality rates have
occurred in developed and developing countries, re-
spectively. The most plausible explanations for the
greater fall in more developed countries may be better
control of risk factors, such as hypertension, obesity,
hypercholesterolemia, and diabetes, promoting better
care, using more effective treatments, and allocating
higher budgets for health services in these areas [16, 36–
38]. On the other hand, rapid economic transition, high
productivity in the economy, and rising per capita in-
come in several developing countries seems to play a
crucial role in the reduction of CVD mortality rate over
the past few decades [39, 40]. These findings are in
agreement with some other research in this field. In a
study by Kollia et al., they reported an approximate 43%
decrease in CVD death rate in developed countries ver-
sus only 13% in developing nations between 1990 and
2013 [37]. Nevertheless, some conflicting results have
been previously reported in different parts of the world.
For example, a study in India showed a rapid increase in
CVD mortality between 1990 and 2016. The authors
have stated that this increase seems to be almost entirely
owing to population aging in this Asian country. Never-
theless, high blood pressure, high total cholesterol, and
high fasting blood glucose level were the major contribu-
tors to CVD mortality in this country [41].
Another noticeable finding is that even though the de-
veloped and developing countries underwent a statisti-
cally significant decline, the developing counties had a
more rather shallow reduction in CVD MIR in compari-
son to developed ones during a 28-year follow-up.
Nonetheless, the downward trend implies that the five-
year survival rate of CVD patients was increased for both
sets of countries. The significant relationship between
HDI and MIR highlights that the countries focused on
improving the adoption of a healthy lifestyle as well as
access to health care services in either prevention or
treatment of CVD, increasing life expectancy, and in-
creasing urbanization during recent years. Socioeco-
nomic status is directly correlated with a patient’s
survival so that patients with higher socioeconomic con-
ditions may experience greater survival [42]. Finally, it is
necessary to highlight that the awareness of CVD has in-
creased in several countries. This helps to improve early
detection of signs and symptoms of CVD, better health
care, and thereby superior prognosis.
Strengths and limitations
In addition to the limitations reported in GBD studies,
the present research encountered some potential limita-
tions. Firstly, lack of precise and reliable data for inci-
dence and mortality rates in some countries, especially
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in less developed regions, entails GBD to report the esti-
mated rates. The second limitation is the small number
of countries in some super regions which makes the
statistical inference (for example, valid estimation of
model parameters) challenging for them. In the previous
decades, a number of studies have shown that occupa-
tional exposure to organic solvents, pesticides, silica
dust, engine exhaust, welding fumes, arsenic, benzopyr-
enes, lead, dynamite, carbon disulfide, carbon monoxide,
metalworking fluids, inorganic mercury, phenoxy acids,
and electrolytic production of aluminum is significantly
associated with different types of cardiovascular diseases
[43–47]. In the present epidemiologic study, we did not
aim to investigate the effect of occupational exposures
on global burden of CVD. We believe that assessment of
this association in all world countries needs more spe-
cialized researches by the experts in the future. This
could be considered as one of the most important limi-
tations of our study. In spite of the aforementioned limi-
tations, our research is a novel and comprehensive study
in this field. The main strength of the present study is
the longitudinal nature of the GBD dataset with a rea-
sonably long period of follow-up with 28 repeated mea-
surements which enables us to obtain more accurate
estimates. Considering this issue, we utilized a more
complex and convenient statistical approach to reach
more reliable inferences. This modeling approach gives
us the opportunity to capture the longitudinal nature of
response data and explanatory variables. However, previ-
ous studies have employed either univariate correlation
coefficients or simple linear regression models to investi-
gate the relationship between the burden of disease indi-
ces and other potential indicators like socio-economic
measures. Lastly, using the MIR index as a proxy for sur-
vival appears to be a reliable approach to explain the dis-
crepancies in age standardized rate of incidence and
mortality from CVD among different geographic areas.
To calculate this index, there is no need to conduct
studies with long-term follow-up which are potentially
time-consuming, expensive, and prone to different
biases. Additionally, it should be noted that based on
our literature review, there was no related research in
this field (the relationship between development factor
and CVD MIR). Hence, more comprehensive researches
should be conducted to assess the cross-sectional and
longitudinal association between the development factor
and CVD MIR (or survival rate of the patients) more
properly.
Conclusions
In summary, we comprehensively described the global
patterns of CVD incidence, mortality, and MIR and ana-
lyzed their temporal trends from 1990 to 2017 via an ad-
vanced statistical technique. Totally, it was found that
the overall CVD incidence and mortality have signifi-
cantly declined over the 28-year study period, while the
mortality-to-incidence ratio was rather stable. This is an
encouraging message for health policymakers among the
total world population; since it reveals that global efforts
for controlling the CVD burden (reducing the CVD inci-
dence and mortality rates) were reasonably successful. In
addition, the quite parallel lines for incidence, mortality,
and MIR trends in developed and developing countries
imply that the gap between these indices in the year
1990 remains fixed until the ending year of the study. In
this context, both countries should put more effort into
lowering these gaps while they attempt to decrease the
slope of the CVD burden indices more rapidly in the
upcoming years.
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